Precision for Medicine (part of the Precision Medicine Group) is the CRO conducting Neuren’s Phase 2 trial in PWS.
To be clear, the PMS and PH trials have been conducted by a different CRO and the Angelman study in Australia by another again.
As stated in the January post, Precision for Medicine is the CRO which was contracted by Acadia for the Phase 3 Rett syndrome trial.
Why Neuren has selected this CRO specifically for the PWS trial is unclear, but may just be because Precision for Medicine has previous experience in PWS trials.
As you alluded to, Precision Medicine Group and Blackstone are indeed linked – Blackstone acquired the Group for US$2.3bn in 2020.
I think it’s fair to assume that Blackstone is well aware of Neuren and its pipeline of neurodevelopmental disorders. It’s probably also fair to assume that Blackstone would welcome Neuren contracting its future clinical studies to Precision for Medicine.
Blackstone Life Sciences says that it has a focus on how companies can reduce the time-to-market for drug development, with the goal of getting medicines to patients faster. It likes rare disease assets and it favours late-stage programs. Reata Pharmaceuticals was one of its strategic investments. Precision Medicine Group also has the stated goal of bringing medicines to patients faster and it is a specialist in rare disease clinical trials. Jon Pilcher has repeatedly stated that Neuren is focused on getting its rare disease treatments to patients as quickly as possible…
Who knows which way it will all fall but one can certainly understand why Blackstone might be keen to talk to Neuren.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)